Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

Pattern of Care and Outcomes of Adolescent and Young Adults with Lymphoma Treated in the Rhône-Alpes Region.

Dony A, Belhabri A, Bertrand Y, Sebban C, Cony-Makhoul P, Sobh M, Rogasik M, Salles G, Anglaret B, Freycon C, Corm S, Faurie P, Cornillon J, Michallet AS, Chassagne-Clément C, Berger F, Ray-Coquard IL.

J Adolesc Young Adult Oncol. 2019 Aug 14. doi: 10.1089/jayao.2019.0016. [Epub ahead of print]

PMID:
31411521
2.

Peripheral blood lymphoagglutination and platelet satellitism in marginal zone lymphomas.

Degaud M, Foucher B, Pichon M, Belhabri A, Daniel M, Vila L.

Int J Lab Hematol. 2019 Apr;41(2):e50-e53. doi: 10.1111/ijlh.12956. Epub 2018 Dec 18. No abstract available.

PMID:
30561878
3.

A new signaling cascade linking BMP4, BMPR1A, ΔNp73 and NANOG impacts on stem-like human cell properties and patient outcome.

Voeltzel T, Flores-Violante M, Zylbersztejn F, Lefort S, Billandon M, Jeanpierre S, Joly S, Fossard G, Milenkov M, Mazurier F, Nehme A, Belhabri A, Paubelle E, Thomas X, Michallet M, Louache F, Nicolini FE, Caron de Fromentel C, Maguer-Satta V.

Cell Death Dis. 2018 Sep 27;9(10):1011. doi: 10.1038/s41419-018-1042-7.

4.

A phase II study of the oral JAK1/JAK2 inhibitor ruxolitinib in advanced relapsed/refractory Hodgkin lymphoma.

Van Den Neste E, André M, Gastinne T, Stamatoullas A, Haioun C, Belhabri A, Reman O, Casasnovas O, Ghesquieres H, Verhoef G, Claessen MJ, Poirel HA, Copin MC, Dubois R, Vandenberghe P, Stoian IA, Cottereau AS, Bailly S, Knoops L, Morschhauser F.

Haematologica. 2018 May;103(5):840-848. doi: 10.3324/haematol.2017.180554. Epub 2018 Jan 19.

5.

Targeting apoptosis in acute myeloid leukaemia.

Cassier PA, Castets M, Belhabri A, Vey N.

Br J Cancer. 2017 Oct 10;117(8):1089-1098. doi: 10.1038/bjc.2017.281. Epub 2017 Aug 24. Review.

6.

Utility of post-therapy brain surveillance imaging in the detection of primary central nervous system lymphoma relapse.

Fossard G, Ferlay C, Nicolas-Virelizier E, Rey P, Ducray F, Jouanneau E, Faurie P, Belhabri A, Sunyack MP, Chassagne-Clément C, Thiesse P, Sebban C, Biron P, Blay JY, Ghesquières H.

Eur J Cancer. 2017 Feb;72:12-19. doi: 10.1016/j.ejca.2016.10.036. Epub 2016 Dec 22.

PMID:
28012348
7.

[Association of lymphoma and granulomatosis: A case series].

de Charry F, Sadoune K, Sebban C, Rey P, de Parisot A, Nicolas-Virelizier E, Belhabri A, Ghesquières H, Ninet J, Faurie P.

Rev Med Interne. 2016 Jul;37(7):453-9. doi: 10.1016/j.revmed.2015.10.344. Epub 2015 Nov 25. French.

PMID:
26611429
8.

Major molecular response achievement in CML Patients can be predicted by BCR-ABL1/ABL1 or BCR-ABL1/GUS ratio at an earlier time point of follow-up than currently recommended.

Huet S, Cony-Makhoul P, Heiblig M, Tigaud I, Gazzo S, Belhabri A, Souche D, Michallet M, Magaud JP, Hayette S, Nicolini F.

PLoS One. 2014 Sep 9;9(9):e106250. doi: 10.1371/journal.pone.0106250. eCollection 2014.

9.

Specific scoring systems to predict survival of patients with high-risk myelodysplastic syndrome (MDS) and de novo acute myeloid leukemia (AML) after intensive antileukemic treatment based on results of the EORTC-GIMEMA AML-10 and intergroup CRIANT studies.

Oosterveld M, Suciu S, Muus P, Germing U, Delforge M, Belhabri A, Aul C, Selleslag D, Ferrant A, Marie JP, Amadori S, Jehn U, Mandelli F, Hess U, Hellström-Lindberg E, Cakmak-Wollgast S, Vignetti M, Labar B, Willemze R, de Witte T.

Ann Hematol. 2015 Jan;94(1):23-34. doi: 10.1007/s00277-014-2177-y. Epub 2014 Aug 7.

PMID:
25096636
10.

Impact of the introduction of rituximab in first-line follicular lymphoma: a retrospective study of 247 unselected patients referred to a single institution with a long-term follow-up.

Nicolas-Virelizier E, Ségura-Ferlay C, Ghesquières H, Chassagne-Clément C, Gargi T, Biron P, Belhabri A, Rey P, Faurie P, Chabaud S, Sebban C.

Hematol Oncol. 2015 Mar;33(1):1-8. doi: 10.1002/hon.2130. Epub 2014 Feb 5.

PMID:
24496668
11.

Value of allogeneic versus autologous stem cell transplantation and chemotherapy in patients with myelodysplastic syndromes and secondary acute myeloid leukemia. Final results of a prospective randomized European Intergroup Trial.

de Witte T, Hagemeijer A, Suciu S, Belhabri A, Delforge M, Kobbe G, Selleslag D, Schouten HC, Ferrant A, Biersack H, Amadori S, Muus P, Jansen JH, Hellström-Lindberg E, Kovacsovics T, Wijermans P, Ossenkoppele G, Gratwohl A, Marie JP, Willemze R.

Haematologica. 2010 Oct;95(10):1754-61. doi: 10.3324/haematol.2009.019182. Epub 2010 May 21.

12.

The presence of an HLA-identical sibling donor has no impact on outcome of patients with high-risk MDS or secondary AML (sAML) treated with intensive chemotherapy followed by transplantation: results of a prospective study of the EORTC, EBMT, SAKK and GIMEMA Leukemia Groups (EORTC study 06921).

Oosterveld M, Suciu S, Verhoef G, Labar B, Belhabri A, Aul C, Selleslag D, Ferrant A, Wijermans P, Mandelli F, Amadori S, Jehn U, Muus P, Zittoun R, Hess U, Anak O, Beeldens F, Willemze R, de Witte T.

Leukemia. 2003 May;17(5):859-68.

PMID:
12750698
13.

Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC/GIMEMAAML-10 trial.

Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B, De Rosa G, Belhabri A, Giustolisi R, Delarue R, Liso V, Mirto S, Leone G, Bourhis JH, Fioritoni G, Jehn U, Amadori S, Fazi P, Hagemeijer A, Willemze R; EORTC and GIMEMA Leukemia Groups.

Blood. 2003 Aug 15;102(4):1232-40. Epub 2003 Apr 24.

PMID:
12714526
14.

The stem cell mobilizing capacity of patients with acute myeloid leukemia in complete remission correlates with relapse risk: results of the EORTC-GIMEMA AML-10 trial.

Keating S, Suciu S, de Witte T, Zittoun R, Mandelli F, Belhabri A, Amadori S, Fibbe W, Gallo E, Fillet G, Varet B, Meloni G, Hagemeijer A, Fazi P, Solbu G, Willemze R; EORTC Leukemia Group; GIMEMA Leukemia Group.

Leukemia. 2003 Jan;17(1):60-7.

15.

Influence of cigarette smoking on the presentation and course of acute myeloid leukemia.

Chelghoum Y, Danaïla C, Belhabri A, Charrin C, Le QH, Michallet M, Fiere D, Thomas X.

Ann Oncol. 2002 Oct;13(10):1621-7.

PMID:
12377652
16.

All trans retinoic acid in combination with intermediate-dose cytarabine and idarubicin in patients with relapsed or refractory non promyelocytic acute myeloid leukemia: a phase II randomized trial.

Belhabri A, Thomas X, Wattel E, Chelghoum Y, Anglaret B, Vekhoff A, Reman O, Dombret H, Dhedin N, Michallet M, Fière D, Archimbaud E.

Hematol J. 2002;3(1):49-55.

PMID:
11960396
17.

Structural rearrangements of chromosome 3 in 57 patients with acute myeloid leukemia: clinical, hematological and cytogenetic features.

Charrin C, Belhabri A, Treille-Ritouet D, Theuil G, Magaud JP, Fiere D, Thomas X.

Hematol J. 2002;3(1):21-31.

PMID:
11960392
18.

Prognostic factors and treatment effects on survival in acute myeloid leukemia of M6 subtype: a retrospective study of 54 cases.

Colita A, Belhabri A, Chelghoum Y, Charrin C, Fiere D, Thomas X.

Ann Oncol. 2001 Apr;12(4):451-5.

PMID:
11398875
19.

[Acute myeloid leukemia in the elderly: a review].

Thomas X, Belhabri A.

Bull Cancer. 2001 Feb;88(2):143-54. Review. French.

20.

Late autologous transplantation in chronic myelogenous leukemia with peripheral blood progenitor cells mobilized by G-CSF and interferon-alpha.

Michallet M, Thiébaut A, Philip I, Charrin C, Vigouroux C, Thomas X, Bilger K, Belhabri A, Guyotat D, Corront B, Salles B, Dumontet C, Péaud PY, Vilque JP, Devidas A, Fière D.

Leukemia. 2000 Dec;14(12):2064-9.

21.

Long-term outcome after allogeneic hematopoietic stem cell transplantation for advanced stage acute myeloblastic leukemia: a retrospective study of 379 patients reported to the Société Française de Greffe de Moelle (SFGM).

Michallet M, Thomas X, Vernant JP, Kuentz M, Socié G, Espérou-Bourdeau H, Milpied N, Blaise D, Rio B, Reiffers J, Jouet JP, Cahn JY, Bourhis JH, Lioure B, Leporrier M, Sotto JJ, Souillet G, Sutton L, Bordigoni P, Dreyfus F, Tilly H, Gratecos N, Attal M, Leprise PY, Déméocq F, Michel G, Buzyn A, Delmas-Marsalet B, Bernaudin F, Ifrah N, Sadoun A, Guyotat D, Cavazzana-Cavo M, Caillot D, De Revel T, Vannier JP, Baruchel A, Fegueux N, Tanguy ML, Thiébaut A, Belhabri A, Archimbaud E.

Bone Marrow Transplant. 2000 Dec;26(11):1157-63.

22.

[Effectiveness of combined vancomycin and pefloxacine in gastrointestinal decontamination for preventing infections after chemotherapy-induced bone marrow aplasia. A randomized double-blind study].

Thomas X, Troncy J, Belhabri A, Thiebaut A, Bouheddou N, Michallet M, Fleurette J, Pivot C, Fiere D, Archimbaud E.

Presse Med. 2000 Oct 28;29(32):1745-51. French.

PMID:
11098268
23.

Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukemia presenting with hyperleukocytosis.

Thiébaut A, Thomas X, Belhabri A, Anglaret B, Archimbaud E.

Ann Hematol. 2000 Sep;79(9):501-6.

PMID:
11043421
24.
25.

Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Société Française de Greffe de moelle (SFGM).

Michallet M, Tanguy ML, Socié G, Thiébaut A, Belhabri A, Milpied N, Reiffers J, Kuentz M, Cahn JY, Blaise D, Demeocq F, Jouet JP, Michallet AS, Ifrah N, Vilmer E, Molina L, Michel G, Lioure B, Cavazzana-Calvo M, Pico JL, Sadoun A, Guyotat D, Attal M, Curé H, Bordigoni P, Sutton L, Buzyn-Veil A, Tilly M, Keoirruer N, Feguex N.

Br J Haematol. 2000 Feb;108(2):400-7.

PMID:
10691873
26.

Continuous-infusion carboplatin in combination with idarubicin or mitoxantrone for high-risk acute myeloid leukemia: a randomised phase II study.

Belhabri A, Thomas X, Troncy J, Assouline D, Michallet M, Wattel E, Tigaud JD, Blanc M, Fière D, Archimbaud E.

Leuk Lymphoma. 1999 Dec;36(1-2):45-55.

PMID:
10613449
28.

Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.

Michallet M, Perrin MC, Belhabri A, Molina L, Nicolini F, Tigaud JD, Sotto JJ, Guyotat D, Fière D, Archimbaud E.

Bone Marrow Transplant. 1999 Jan;23(2):145-50.

29.

Hypermethylation of calcitonin gene in adult acute leukemia at diagnosis and during complete remission.

Thomas X, Teillon MH, Belhabri A, Rimokh R, Fiere D, Magaud JP, Archimbaud E.

Hematol Cell Ther. 1999 Feb;41(1):19-26.

PMID:
10193642
30.

Pharmacokinetics of itraconazole oral solution in allogeneic bone marrow transplant patients receiving total body irradiation.

Michallet M, Persat F, Kranzhöfer N, Levron JC, Prat C, Belhabri A, Chwetzoff E, Le Moing JP, Fiere D, Piens MA.

Bone Marrow Transplant. 1998 Jun;21(12):1239-43.

31.

Improvement of prognosis in refractory and relapsed acute promyelocytic leukemia over recent years: the role of all-trans retinoic acid therapy.

Thomas X, Anglaret B, Thiebaut A, Belhabri A, Treille-Ritouet D, Fiere D, Archimbaud E.

Ann Hematol. 1997 Nov-Dec;75(5-6):195-200.

PMID:
9433375
32.

Granulocyte colony-stimulating factor given in addition to interferon-alpha to mobilize peripheral blood stem cells for autologous transplantation in chronic myeloid leukaemia.

Archimbaud E, Michallet M, Philip I, Charrin C, Clapisson G, Belhabri A, Guilhot F, Stryckmans P, Adeleine P, Fière D.

Br J Haematol. 1997 Dec;99(3):678-84.

PMID:
9401084

Supplemental Content

Loading ...
Support Center